SCHEMBL2054586

SCHEMBL2054586

O=C(O)Cn1c(=O)n2c3c(cnc(Cl)c31)NC(=O)C2

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ RAB9A P51151 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ CALCRL Q16602 3/20 0.32
▸ MITF O75030 1/20 0.32
▸ S1PR4 O95977 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ S1PR1 P21453 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ PAX8 Q06710 1/20 0.32
▸ ADORA2B P29275 1/20 0.32
▸ KDM4E B2RXH2 5/20 0.31
▸ HPGD P15428 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ APEX1 P27695 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL261374 0.78 APEX1 (0.38) ALDH1A1CALCRLADORA2BKDM4EHPGD
SCHEMBL261366 0.71 CALCRL (0.52) ALDH1A1CALCRLHTTKDM4EKMT2A
SCHEMBL261105 0.70 CALCRL (0.42) ALDH1A1CALCRLADORA2BKDM4EHPGD
SCHEMBL261372 0.69 APEX1 (0.40) ALDH1A1CALCRLPOLBKDM4EAPEX1
SCHEMBL260034 0.66 CALCRL (0.37) CALCRL
SCHEMBL280533 0.62 GSK3B (0.37) CALCRL
SCHEMBL261544 0.61 CALCRL (0.32) CALCRL
SCHEMBL261349 0.59 CALCRL (0.51) ALDH1A1CALCRLHTTKDM4EMEN1
SCHEMBL30937588 0.59 ACE (0.48) ALDH1A1SMN1; SMN2LMNAPOLBMAPT
SCHEMBL8345781 0.59 TSHR (0.39) ALDH1A1LMNAPOLBKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163752-B2 Tricyclic anilide heterocyclic CGRP receptor antagonists Merck, Sharp & Dohme Corp. (US) 2012-04-24 — — US disclosed
US-8163752-B2 Tricyclic anilide heterocyclic CGRP receptor antagonists Merck, Sharp & Dohme Corp. (US) 2012-04-24 — — US disclosed
US-20100137328-A1 TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2010-06-03 — — US disclosed
US-20100137328-A1 TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2010-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137328-A1 TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS BDKRB1, CCKBR, BDKRB2 ALDH1A1 1622/4885L3MBTL1 3025/4885RAB9A 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback